Literature DB >> 18516757

Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors.

Scott N Pinchot1, Susan C Pitt, Rebecca S Sippel, Muthusamy Kunnimalaiyaan, Herbert Chen.   

Abstract

Gastrointestinal (GI) neuroendocrine tumors (NETs), for example, carcinoids, are rare neoplasms characterized by the production of bioactive markers, such as 5-HT and chromogranin A. With the exception of surgery, there are limited curative and palliative treatments available for this type of tumor. Therefore, there is a great need to develop new pharmacological strategies to reduce tumor burden and control symptoms in patients with metastatic carcinoid tumors and the carcinoid syndrome. In this review, several pathways thought to be involved in GI NET carcinogenesis are discussed, and novel approaches that are currently in development to target these pathways are highlighted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18516757      PMCID： PMC2905744     

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  37 in total

Review 1.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 2.  Notch signaling: the demise of elegant simplicity.

Authors:  Tom Kadesch
Journal:  Curr Opin Genet Dev       Date:  2004-10       Impact factor: 5.578

3.  Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.

Authors:  M Fujimori; S Ikeda; Y Shimizu; M Okajima; T Asahara
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

Authors:  Muthusamy Kunnimalaiyaan; Mary Ndiaye; Herbert Chen
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

5.  Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis.

Authors:  Gordon P Meares; Richard S Jope
Journal:  J Biol Chem       Date:  2007-04-16       Impact factor: 5.157

6.  Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor.

Authors:  Min-Cheng Su; Chia-Chi Wang; Chun-Chin Chen; Rey-Heng Hu; Ting-Huang Wang; Hsin-Lien Kao; Yung-Ming Jeng; Ray-Hwang Yuan
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

7.  The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors.

Authors:  N Younes; N Fulton; R Tanaka; J Wayne; F H Straus; E L Kaplan
Journal:  Cancer       Date:  1997-05-01       Impact factor: 6.860

8.  Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.

Authors:  David Yu Greenblatt; Max Cayo; Li Ning; Renata Jaskula-Sztul; Megan Haymart; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Gastrointest Surg       Date:  2007-09-15       Impact factor: 3.452

9.  Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells.

Authors:  Rebecca S Sippel; Jennifer E Carpenter; Muthusamy Kunnimalaiyaan; Sara Lagerholm; Herbert Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-08       Impact factor: 4.052

10.  GSK-3 inhibitors induce chromosome instability.

Authors:  Anthony Tighe; Arpita Ray-Sinha; Oliver D Staples; Stephen S Taylor
Journal:  BMC Cell Biol       Date:  2007-08-14       Impact factor: 4.241
View more
  15 in total

1.  Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Authors:  Scott N Pinchot; Renata Jaskula-Sztul; Li Ning; Noel R Peters; Mackenzie R Cook; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Authors:  Yash Somnay; Kevin Simon; April D Harrison; Selvi Kunnimalaiyaan; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

3.  Lithium inhibits carcinoid cell growth in vitro.

Authors:  David Yu Greenblatt; Mary Ndiaye; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

4.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

5.  Hepatic neuroendocrine metastases: chemo- or bland embolization?

Authors:  Susan C Pitt; Jaime Knuth; James M Keily; John C McDermott; Sharon M Weber; Hebert Chen; William S Rilling; Edward J Quebbeman; David M Agarwal; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2008-08-16       Impact factor: 3.452

6.  Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.

Authors:  Joel T Adler; Mackenzie Cook; Yinggang Luo; Susan C Pitt; Jianhua Ju; Wenli Li; Ben Shen; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

7.  An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Authors:  Kanika A Bowen; Scott R Silva; Jessica N Johnson; Hung Q Doan; Lindsey N Jackson; Pat Gulhati; Suimin Qiu; Taylor S Riall; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

8.  Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging.

Authors:  Guojun Chen; Renata Jaskula-Sztul; Corinne R Esquibel; Irene Lou; Qifeng Zheng; Ajitha Dammalapati; April Harrison; Kevin W Eliceiri; Weiping Tang; Herbert Chen; Shaoqin Gong
Journal:  Adv Funct Mater       Date:  2017-01-17       Impact factor: 18.808

9.  Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway.

Authors:  Scott N Pinchot; Joel T Adler; Yinggang Luo; Jianhua Ju; Wenli Li; Ben Shen; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Surg       Date:  2009-03       Impact factor: 2.565

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.